Home

AMARIN CORPORATION

Amarin is a clinical-stage biopharmaceutical company with the lead program entering Phase 3 for hypertriglyceridemia. Amarin’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease.

AMR101 for Hypertriglyceridemia

AMR101, a prescription grade Omega-3 fatty acid, is an ultra pure (~97%) ethyl ester of eicosapentaenoic acid. Phase 3 development of AMR101 in hypertriglyceridemia is planned to commence in 2009. Hypertriglyceridemia is a condition associated with increased levels of heart disease diagnosed in over 10 million people in the US.

read more
Download